New CF drug combo VX-828 enters early human testing

NCT ID NCT06154447

Completed Disease control Sponsor: Vertex Pharmaceuticals Incorporated Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This early-stage study tests the safety and how the body handles a new drug called VX-828, alone or combined with other CF medicines. It involves about 165 healthy adults and people with cystic fibrosis. The goal is to see if VX-828 is safe enough for further testing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cystic fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CYSTIC FIBROSIS

Contacts and locations

Locations

AdventHealth Medical Group Pulmonology at Orlando Ridgewood

Orlando, Florida, 32803, United States
Altasciences Clinical Kansas

Overland Park, Kansas, 66212, United States
Billings Clinic, Pediatric Pulmonary Dept.

Billings, Montana, 59101, United States
Boston Children's Hospital

Boston, Massachusetts, 02115, United States
Cook Children's Pulmonology

Fort Worth, Texas, 76104, United States
Joe DiMaggio Cycstic Fibrosis & Pulmonary Center

Hollywood, Florida, 33021, United States
Kentucky Children's Hospital

Lexington, Kentucky, 40508, United States
New York Medical College

Hawthorne, New York, 10532, United States
ProMedica Toledo Children's Hospital & ProMedica Central Physicians, LLC

Toledo, Ohio, 43606, United States
University of Minnesota -Pulmonology

Minneapolis, Minnesota, 55455, United States
University of Utah Hospital - Pulmonology

Salt Lake City, Utah, 84132, United States
Vermont Lung Center

Colchester, Vermont, 05446, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.